Jeffrey S. McCombs, PhD 
Associate Professor of Pharmaceutical and Health Economics & Director of Graduate Studies | USC School of Pharmacy
Los Angeles, CA, UNITED STATES
Dr. Jeffrey McCombs' research focuses on pharmaceutical economics and pharmaceutical policy.
Biography
Jeff McCombs is an associate professor at the USC School of Pharmacy in the Department of Pharmaceutical and Health Economics. He holds joint appointments in the USC Leonard Davis School of Gerontology and the USC Price School of Public Policy. He earned his doctorate in economics at the University of California-San Diego (UCSD), specializing in health economics.
At UCSD, McCombs received cross training at the School of Medicine through a National Center for Health Services Research pre-doctoral traineeship. His previous positions include: assistant professor, Department of Mental Hygiene, the Johns Hopkins School of Hygiene and Public Health (1980-'82); senior project analyst, Applied Management Sciences, Silver Spring, Maryland (1982-83); and social science research analyst, Office of Research and Demonstrations, the Health Care Financing Administration (1983-87).
McCombs is an author or co-author of articles appearing in the Journal of Health Economics, the Journal of Health Politics, Policy and Law, Health Care Financing Review, Health Affairs, Value in Health, Health Services Research, Psychiatric Services, the Journal of Clinical Psychiatry, Medical Care, Annals of Pharmacotherapy and the American Journal of Health Systems Pharmacy. He has also authored or co-authored numerous book chapters and has served as a consultant to the Health Care Financing Administration and several pharmaceutical companies.
Areas of Expertise (7)
Health Care Reform
Outcomes Research
Pharmaceutical Economics
Epidemiology
Pharmaceutical Policy
Health Services Research
Pharmaceutical Pricing
Education (2)
University of California, San Diego: Ph.D., Economics 1982
University of California, San Diego: B.A., Economics 1970
Affiliations (1)
- ISPOR Fellowship Standards Task Force
Links (2)
Selected Media Appearances (1)
Pharmacists with greater role curtail repeat hospital visits, study finds
USC News
2017-03-17
“This is the latest study to show that expanding the scope of practice for pharmacists could help patients and still save the health system money,” said corresponding author Jeff McCombs, an associate professor at the USC School of Pharmacy and researcher at the USC Schaeffer Center for Health Policy and Economics. “The evidence is clear that community-based pharmacists can reduce health costs. The question is: Who will pay for expanding their role beyond dispensing medications at the counter?”
Selected Articles (3)
Improving Model Specifications When Estimating Treatment Effects across Alternative Medical Interventions
Open Journal of StatisticsYawen Jiang, Jeffrey McCombs
2014 The purpose of this paper is to critique the list of independent variables commonly used in observational research and test the impact of variables for prior use and treatment history on estimates of treatment effects.
Defining and measuring clinical effectiveness in the treatment of schizophrenia
American Psychiatric PublishingHenry A Nasrallah, Steven D Targum, Rajiv Tandon, Jeffrey S McCombs, Ruth Ross
2014 Expectations in treating schizophrenia are expanding beyond just controlling psychotic symptoms to include functional recovery. This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives.
The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry
JAMA Internal MedicineJeffrey McCombs, Tara Matsuda, Ivy Tonnu-Mihara, Sammy Saab, Patricia Hines, Gilbert L’Italien, Timothy Juday, Yong Yuan
2014 The impact of viral load suppression, genotype, race, and other factors on the risk of late-stage liver-related events in patients with hepatitis C (HCV) has been assessed previously using data from small observational cohorts or clinical trials. Data from large real-world practice samples are needed to improve risk factor estimates for late-stage liver events and death in HCV.
Social Media